PEDIATRIC ONCOLOGY GROUP

儿科肿瘤组

基本信息

  • 批准号:
    3556929
  • 负责人:
  • 金额:
    $ 12.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1980
  • 资助国家:
    美国
  • 起止时间:
    1980-07-01 至 1990-12-31
  • 项目状态:
    已结题

项目摘要

This proposal represents a request to support participation in the Pediatric Oncology Group (POG). This cooperative research is devoted to the investigation of chemotherapeutic approaches to acute leukemia and other neoplastic diseases of childhood. Significant palliation and prolongation of survival has been achieved and contributions have been made in clinical pharmacology. However, the real objective of these studies is the eradication of neoplastic diseases by treatment. Studies are being designed to reflect an increasing intensity of attack on the neoplastic cell. The cooperative group technique permits prompt evaluation in series of reasonable size of promising leads in chemotherapy. These leads or new approaches are often suggested by the results of the group's own work in clinical oncology. Thus, a completed protocol often suggests the new avenues to be explored in new protocols. In addition, protocols are designed to exploit maximal clinical or conceptual advances made in experimental animals and/or clinical pilot studies. The Division of Pediatric Hematology-Oncology in the Department of Pediatrics at the University of California, San Diego (UCSD) has a 10 year involvement in cooperative group studies with Cancer and Leukemia Group B prior to joining forces with the Pediatric Oncology Group in 1980. Between January 1, 1983 and December 31, 1984, we have had 129 patient registrations on 26 group protocol studies. In addition, the P.I. coordinated a Phase II study o n VP-16-213 and completed a draft on a Group Protocol study on the treatment of early stage Hodgkin's disease, and other UCSD investigators served as coordinators for Group Protocols on germ cell tumors, bone marrow transplantation for patients with ALL in second remission or involved in the laboratory investigation of Group Protocol studies in T-cell ALL or neuroblastoma. We plan to continue our active participation in all phases of POG activities.
这一提议是一项要求,要求支持参加

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FAITH H KUNG其他文献

FAITH H KUNG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FAITH H KUNG', 18)}}的其他基金

POG 9575 TOPOTECAN FOR REFRACTORY LEUKEMIA
POG 9575 拓扑替康治疗难治性白血病
  • 批准号:
    6265148
  • 财政年份:
    1998
  • 资助金额:
    $ 12.35万
  • 项目类别:
POG 9426 TREATMENT OF HODGKINS DISEASE WITH DBVE AND IRRADIATION
POG 9426 用 DBVE 和辐射治疗霍奇金病
  • 批准号:
    6279252
  • 财政年份:
    1997
  • 资助金额:
    $ 12.35万
  • 项目类别:
POG 9572 BYROSTATIN IN CHILDREN WITH SOLID TUMORS
POG 9572 拜罗他汀治疗患有实体瘤的儿童
  • 批准号:
    6279206
  • 财政年份:
    1997
  • 资助金额:
    $ 12.35万
  • 项目类别:
POG 9571 IRINOTECAN IN CHILDREN WITH SOLID TUMORS
POG 9571 伊立替康治疗患有实体瘤的儿童
  • 批准号:
    6279207
  • 财政年份:
    1997
  • 资助金额:
    $ 12.35万
  • 项目类别:
POG9470--CI 980 IN CHILDREN WITH SOLID TUMORS
POG9470--CI 980 用于患有实体瘤的儿童
  • 批准号:
    6279171
  • 财政年份:
    1997
  • 资助金额:
    $ 12.35万
  • 项目类别:
POG9470--CI 980 IN CHILDREN WITH SOLID TUMORS
POG9470--CI 980 用于患有实体瘤的儿童
  • 批准号:
    6249197
  • 财政年份:
    1997
  • 资助金额:
    $ 12.35万
  • 项目类别:
PEDIATRIC ONCOLOGY GROUP
儿科肿瘤组
  • 批准号:
    3556926
  • 财政年份:
    1980
  • 资助金额:
    $ 12.35万
  • 项目类别:
PEDIATRIC ONCOLOGY GROUP
儿科肿瘤组
  • 批准号:
    3556930
  • 财政年份:
    1980
  • 资助金额:
    $ 12.35万
  • 项目类别:
PEDIATRIC ONCOLOGY GROUP
儿科肿瘤组
  • 批准号:
    6489030
  • 财政年份:
    1980
  • 资助金额:
    $ 12.35万
  • 项目类别:
PEDIATRIC ONCOLOGY GROUP
儿科肿瘤组
  • 批准号:
    2633728
  • 财政年份:
    1980
  • 资助金额:
    $ 12.35万
  • 项目类别:

相似海外基金

GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
  • 批准号:
    8653055
  • 财政年份:
    2014
  • 资助金额:
    $ 12.35万
  • 项目类别:
The role of activation-induced cytidine deaminase (AID) mediated DNA damage in the pathogenesis of Burkitt's Lymphoma
活化诱导胞苷脱氨酶 (AID) 介导的 DNA 损伤在伯基特淋巴瘤发病机制中的作用
  • 批准号:
    258438392
  • 财政年份:
    2014
  • 资助金额:
    $ 12.35万
  • 项目类别:
    Research Fellowships
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
  • 批准号:
    8788701
  • 财政年份:
    2014
  • 资助金额:
    $ 12.35万
  • 项目类别:
The interaction of Burkitt's lymphoma cofactors EBV and Plasmodium
伯基特淋巴瘤辅助因子 EBV 和疟原虫的相互作用
  • 批准号:
    8846480
  • 财政年份:
    2012
  • 资助金额:
    $ 12.35万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7289830
  • 财政年份:
    2006
  • 资助金额:
    $ 12.35万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7097879
  • 财政年份:
    2006
  • 资助金额:
    $ 12.35万
  • 项目类别:
REGULATION OF EBV TRANSCRIPTION IN BURKITT'S LYMPHOMA
伯基特淋巴瘤中 EBV 转录的调控
  • 批准号:
    7349162
  • 财政年份:
    2006
  • 资助金额:
    $ 12.35万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7684750
  • 财政年份:
    2006
  • 资助金额:
    $ 12.35万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7492826
  • 财政年份:
    2006
  • 资助金额:
    $ 12.35万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7935180
  • 财政年份:
    2006
  • 资助金额:
    $ 12.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了